Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis

N. Malecic, H. S. Young

Research output: Contribution to journalReview articlepeer-review

332 Downloads (Pure)


Introduction: Affecting 1 million people in the UK, psoriasis is a commonly diagnosed inflammatory disease arising from autoimmune processes that are triggered by environmental factors in genetically susceptible individuals. The pathophysiology of psoriasis has been widely studied and there is evidence that angiogenesis is a key component.Areas covered: In this review the role of vascular endothelial growth factor-A (VEGF), as a key angiogenic mediator in psoriasis pathogenesis is discussed. VEGF is found in higher levels in plaques, normal skin and plasma of patients with psoriasis. The level of VEGF also fluctuates in accordance with disease activity and in response to conventional treatments. There are several VEGF inhibitors currently licenced for use; primarily in the fields of oncology and there are case reports of patients being treated with these therapies for metastatic cancer who have demonstrated significant improvement in their psoriasis. VEGF inhibitory agents have suggested promising utility for the treatment of psoriasis following animal studies.Expert opinion: VEGF may represent a novel treatment target in psoriasis. However, VEGF inhibitors can cause significant side effects such as hypertension and left ventricular dysfunction. The risks of treatment must be carefully evaluated before VEGF inhibitors are trialled or advocated for psoriasis.

Original languageEnglish
Pages (from-to)455-462
Number of pages8
JournalExpert Opinion on Investigational Drugs
Issue number4
Early online date11 Feb 2016
Publication statusPublished - 2016


  • angiogenesis
  • Psoriasis
  • treatment
  • vascular endothelial growth factor
  • VEGF


Dive into the research topics of 'Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis'. Together they form a unique fingerprint.

Cite this